Application of CDK4/6 Inhibitors in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: a Real-World Experience

被引：0

作者：

Kurbacher, Christian M. ^{[1
]}

Fischer, Lotta Ada ^{[2
]}

Heinrich, Georg ^{[3
]}

Herz, Susanne ^{[1
]}

Schott, Alexander ^{[1
]}

Kurbacher, A. Tabea ^{[1
]}

Kurbacher, Jutta Anna ^{[4
]}

Rudlowski, Christian ^{[5
]}

Warm, Mathias R. ^{[2
]}

机构：

[1] Gynakol Zentrum Bonn Friedenspl, Gynakol Schwerpunkt Gynakol Onkol 1, Bonn, Germany

[2] Stadt Klinikum Holweide, Brustzentrum, Cologne, Germany

[3] Praxis Gynakol Onkol, Furstenwalde, Germany

[4] Gynakol Zentrum Bonn Friedenspl, Gynakol Allgemeine Gynakol & Geburtshilfe 2, Bonn, Germany

[5] Evangel Krankenhaus Bergisch Gladbach, Frauenklin, Bergisch Gladbach, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

552

引用

页码：19 / 19

页数：1

共 50 条

[1] TREATMENT OF PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WITH AN CDK4/6 INHIBITOR COMBINED WITH ENDOCRINE AGENTS: A REAL-WORLD EXPERIENCE
Kurbacher, Christian Martin
Fischer, Lotta Ada
Heinrich, Georg
Warm, Mathias
Schott, Alexander
Kurbacher, A. Tabea
Kurbacher, Jutta Anna
Rudlowski, Christian
BREAST, 2019, 48 : S55 - S56
[2] Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Kimmick, G.
Pilehvari, A.
You, W.
Bonilla, G.
Anderson, R.
ANNALS OF ONCOLOGY, 2023, 34 : S373 - S373
[3] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
Forstmeyer, D.
ONKOLOGE, 2016, 22 (07): : 507 - 508
[4] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino, Adriana
Amaro, Carla
Verma, Sunil
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[5] CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
Fedele, Palma
Cinieri, Saverio
FUTURE MEDICINAL CHEMISTRY, 2019, 11 (11) : 1237 - 1239
[6] Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Pla, Helena
Felip, Eudald
Obadia, Veronica
Pernas, Sonia
Vinas, Gemma
Margeli, Mireia
Fort-Culillas, Roser
Del Barco, Sonia
Sabate, Nuria
Fort, Eduard
Lezcano, Clara
Cirauqui, Beatriz
Quiroga, Vanesa
Stradella, Agostina
Gil, Miguel Gil
Esteve, Anna
Recalde, Sabela
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1748 - 1758
[7] Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence
Jeong, J. H.
Jeong, H.
Kim, J. E.
Ahn, J-H.
Jung, K. H.
Kim, S-B.
ANNALS OF ONCOLOGY, 2021, 32 : S72 - S73
[8] The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
Shah, Ami N.
Lim, Bora
Mita, Monica M.
Mauer, Elizabeth
Layng, Kayla V.
Chao, Calvin
Brufsky, Adam M.
CANCER RESEARCH, 2023, 83 (05)
[9] Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
Chen, Bo-Fang
Tsai, Yi-Fang
Chao, Ta-Chung
Lien, Pei-Ju
Lin, Yen-Shu
Feng, Chin-Jung
Chen, Yen-Jen
Cheng, Han-Fang
Liu, Chun-Yu
Lai, Jiun-, I
Tseng, Ling-Ming
Huang, Chi-Cheng
CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
[10] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
Grinshpun, Albert
Tolaney, Sara M. M.
Burstein, Harold J. J.
Jeselsohn, Rinath
Mayer, Erica L. L.
NPJ BREAST CANCER, 2023, 9 (01)

← 1 2 3 4 5 →